LOVENOX
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
May 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
Priority Review
LOVENOX by Sanofi is properties. Approved for deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): • in patients undergoing abdominal surgery, during and 3 more indications. First approved in 2007.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOVENOX (enoxaparin) is an injectable anticoagulant used to prevent and treat venous thrombosis and thromboembolic complications. It works by inhibiting clotting factor activity through its small-molecule mechanism of action. The drug is administered via injection for acute and prophylactic indications in hospitalized and ambulatory patients.
$0.653MPart D
LOE ApproachingLOE approaching signals defensive positioning; smaller linked job count (2 roles) indicates mature-stage operations focus rather than growth expansion.
Mechanism of Action
properties.
Worked on LOVENOX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.